Cartesian Therapeutics, Inc. (RNAC) Tuesday said it has entered into securities purchase agreement for $130 million private investment in public equity or PIPE financing.
Cartesian plans to use the net proceeds to fund its pipeline programs, for working capital, and for general corporate purposes.
As per the agreement, the company is selling 3.56 million of its common shares and 2.94 million of series B preferred stock, both at $20 per share. Each share of series B preferred stock is convertible into one common share.
The financiers comprises both new and existing investors including HBM Healthcare Investments (Cayman) Ltd., Invus, Schooner Capital, Surveyor Capital, Timothy A. Springer, a leading mutual fund manager, and other institutional investors.
Leerink Partners and TD Cowen are acting as lead placement agents for the PIPE financing, which is expected to close by July 3, 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.